17 completed, 8 unknown, 5 terminated, 5 withdrawn. 38 Phase 2, 9 Phase 3, 6 Phase 1.
Follow SARS-CoV2: new trials by email Literature Review of SARS-CoV2 trials Research Report on SARS-CoV2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3 - SARS-CoV2, COVID-19 | Phase 2 | Active not recruiting | Vaxart | 5485 | 2024-10-08 | 2026-10-09 |
| Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19 | Phase 2 / Phase 3 | Unknown | The Scientific and Technological Research Council of Turkey | 100 | 2021-04-01 | 2021-04-02 |
| Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS Rapamycin, Placebo - Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure | Phase 1 / Phase 2 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2021-04-01 | 2021-06-01 | |
| Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) Mesenchymal Stromal Cells, Supportive Care - Sars-CoV2, Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 28 | 2021-02-12 | 2026-10-21 |
| Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Ivermectin Injectable Solution, Injectable Placebo, Zinc - Coronavirus Infection, COVID | Phase 1 / Phase 2 | Unknown | Sohaib Ashraf | 180 | 2020-11-14 | 2021-02-17 |
| Methylene Blue Treatment of COVID-19 Methylene Blue, Control Test - SARS-CoV2 | Phase 2 | Completed | Fondazione Epatocentro Ticino | 29 | 2020-11-05 | 2025-08-17 |
| LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) LSALT peptide, Placebo - COVID, Severe Acute Respiratory Syndrome | Phase 2 | Completed | Arch Biopartners Inc. | 61 | 2020-10-14 | 2025-07-09 |
| Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers Previfenon®, Placebo - COVID-19, SARS-CoV2 | Phase 2 / Phase 3 | Withdrawn | MELISA Institute Genomics & Proteomics Research SpA | 2020-09-30 | 2026-10-19 | |
| Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease N-acetylcysteine - COVID, Sars-CoV2 | Phase 2 | Completed | Cambridge Health Alliance | 165 | 2020-09-23 | 2021-05-28 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebos - COVID-19, Sars-CoV2 | Phase 2 | Completed | Virginia Commonwealth University | 2 | 2020-09-02 | 2021-08-11 |
| Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Hydroxychloroquine Only Product in Oral Dose Form - Sars-CoV2, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | University of Malaga | 1930 | 2020-09-01 | 2020-09-29 |
| Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia Low dose radiation 35 cGy, High dose radiation 100 cGy - Covid-19, Sars-CoV2 | Phase 2 | Active not recruiting | Ohio State University | 37 | 2020-08-28 | 2026-04-16 |
| Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients BIO101, Placebo - Covid-19, SARS-CoV2 | Phase 2 / Phase 3 | Terminated | Biophytis | 238 | 2020-08-26 | 2026-08-12 |
| Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19 Janus Kinase Inhibitor (ruxolitinib), Placebo - Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2 | Phase 2 / Phase 3 | Terminated | Vanderson Geraldo Rocha | 5 | 2020-08-14 | 2021-04-08 |
| Rhu-pGSN for Severe Covid-19 Pneumonia Recombinant human plasma gelsolin (Rhu-pGSN), Placebo - Sars-CoV2 | Phase 2 | Completed | BioAegis Therapeutics Inc. | 64 | 2020-07-30 | 2023-11-28 |
| Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation Vitamins, Telmisartan, Ciclesonide - Corona Virus Infection, Sars-CoV2 | Phase 2 / Phase 3 | Completed | University Hospital, Bordeaux | 412 | 2020-07-29 | 2026-05-12 |
| Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19 Favipiravir, Placebo, Standard of care treatment - Sars-CoV2, COVID-19 | Phase 2 | Completed | Stanford University | 149 | 2020-07-12 | 2022-07-13 |
| CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms Cannabidiol, PLACEBO - SARS-CoV2 | Phase 2 / Phase 3 | Unknown | University of Sao Paulo | 100 | 2020-07-06 | 2021-09-28 |
| Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 SARS-CoV-2 convalescent plasma treatment, Standard care - Sars-CoV2, Covid-19 | Phase 2 / Phase 3 | Unknown | Fundación Santa Fe de Bogota | 236 | 2020-07-01 | 2020-06-11 |
| HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19 Hydroxychloroquine and Azithromycin - Sars-CoV2 | Phase 2 | Withdrawn | Latin American Cooperative Oncology Group | 2020-06-30 | 2020-10-05 |
Showing 20 of 38. Sign in to see all of them.
COVID-19 (28) · Coronavirus Infections (9) · Respiratory Distress Syndrome (8) · Pneumonia (4) · Pneumonia, Viral (3) · Severe Acute Respiratory Syndrome (3) · Acute Lung Injury (2) · Cytokine Release Syndrome (2) · Respiratory Insufficiency (2) · Acute Kidney Injury (1) · Diabetes Mellitus (1) · Heart Diseases (1) · Hematologic Neoplasms (1) · Kidney Diseases (1) · Liver Diseases (1)
Coronaviridae Infections (30) · Infections (30) · Nidovirales Infections (30) · RNA Virus Infections (30) · Virus Diseases (30) · Respiratory Tract Diseases (29) · Respiratory Tract Infections (29) · Lung Diseases (28) · Pneumonia, Viral (25) · Pneumonia (24) · Coronavirus Infections (21) · Respiration Disorders (8) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Hemic and Lymphatic Diseases (2)
Hydroxychloroquine (4) · Zinc (3) · Ascorbic Acid (2) · Azithromycin (2) · COVID-19 Serotherapy (2) · Ivermectin (2) · Saline Solution (2) · Vitamin D (2) · ciclesonide (2) · favipiravir (2) · mavrilimumab (2) · Acetylcysteine (1) · Artesunate (1) · BNT162 Vaccine (1) · Cannabidiol (1)
ProgenaBiome (2) · Andalusian Network for Design and Translation of Advanced Therapies (1) · Apellis Pharmaceuticals, Inc. (1) · Arch Biopartners Inc. (1) · Baylor College of Medicine (1) · BioAegis Therapeutics Inc. (1) · Biophytis (1) · Cambridge Health Alliance (1) · Catalysis SL (1) · Columbia University (1) · Fondazione Epatocentro Ticino (1) · Fundación Santa Fe de Bogota (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Instituto Nacional de Cancerologia de Mexico (1) · Karolinska Institutet (1)
United States (17) · Brazil (6) · France (3) · Canada (2) · Colombia (2) · Spain (2) · Sweden (2) · Turkey (Türkiye) (2) · Belarus (1) · Belgium (1) · Ecuador (1) · Germany (1) · Italy (1) · Mexico (1) · Pakistan (1)
Sabine Hazan, MD (2) · Anders Kjellberg, MD (1) · Andrei Y Hancharou, Dr. (1) · Annie Leutkemeyer, MD (1) · Antonio Abbate, MD, PhD (1) · Arnab Chakravarti, MD (1) · Capucine Morelot-Panzini, MD (1) · Daniel P Andersson, MD, PhD (1) · Dean L Kellogg, MD, PhD (1) · Eduard A Dotsenko, Dr., prof. (1) · Elard S Koch, PhD (1) · Genovefa Papanicolaou, MD (1) · Helen Heslop, MD (1) · James Cummings, MD (1)
PMID 32555385, PMID 32788708, PMID 33050924, PMID 33430924, PMID 33556319, PMID 33624010, PMID 33754144, PMID 34226219, PMID 34473343, PMID 34488858, PMID 34619044, PMID 34992881, PMID 35446944, PMID 36813503, PMID 37510965, PMID 38454482, PMID 38490660, PMID 38545090, PMID 39393522